Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase IIa study of masupirdine in moderate Alzheimer's disease misses primary endpoint

Dec. 3, 2019

Neurocrine Biosciences and Xenon collaborate to develop first-in-class treatments for epilepsy

Dec. 3, 2019

Meta-analysis reveals universally altered genes in early AD

Dec. 3, 2019

Concert initiates phase II study of CTP-692 as adjunctive treatment in schizophrenia

Dec. 2, 2019

Bionomics presents Nav1.7 channel blockers

Nov. 29, 2019

Enrollment ongoing in phase II study of ciprofloxacin/celecoxib fixed-dose combination

Nov. 29, 2019

New analgesic target and lead compound identified in rodents

Nov. 29, 2019

Microbiome ineffective at remyelination support

Nov. 28, 2019

FDA approves Exservan oral film for the treatment of ALS

Nov. 27, 2019

FDA approves advancement of Plenitude study with PPP-001

Nov. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...